 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...4849505152535455565758...858859» |
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial primary completion date, Adherence: A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis (clinicaltrials.gov) - Jul 17, 2024
P=N/A, N=1, Not yet recruiting, Sponsor: Pfizer
Trial primary completion date: Apr 2024 --> Dec 2024
- | Ibrance (palbociclib) / Pfizer, ganitumab (AMG 479) / Takeda, ImmunityBio
Trial termination: Palbociclib + Ganitumab In Ewing Sarcoma (clinicaltrials.gov) - Jul 17, 2024
P2, N=10, Terminated, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Apr 2024 --> Dec 2024 Completed --> Terminated; The study closed early due to discontinuation of ganitumab supply.
- || AMG 193 / Amgen
Trial completion date, Trial primary completion date: AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (clinicaltrials.gov) - Jul 17, 2024
P1, N=500, Recruiting, Sponsor: Amgen
Completed --> Terminated; The study closed early due to discontinuation of ganitumab supply. Trial completion date: Nov 2029 --> May 2032 | Trial primary completion date: Nov 2026 --> May 2029
- || Tepezza (teprotumumab-trbw) / Roche, Amgen, teprotumumab subcutaneous / Xeris Biopharma
Trial completion date: HZNP-TEP-305: A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease (clinicaltrials.gov) - Jul 17, 2024
P3, N=80, Recruiting, Sponsor: Amgen
Trial completion date: Nov 2029 --> May 2032 | Trial primary completion date: Nov 2026 --> May 2029 Trial completion date: Mar 2026 --> Sep 2025
- || Lumakras (sotorasib) / Amgen
PK/PD data, Journal: Impact of a High-Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor. (Pubmed Central) - Jul 17, 2024
Sotorasib was well tolerated in fast and fed conditions. The impact of a high-fat meal on sotorasib exposure is less than a 2-fold increase or decrease in Cmax and AUCs.
- || ivabradine / Generic mfg.
Clinical, Journal: A randomized controlled trial of ivabradine in patients with acute myocardial infarction related cardiogenic shock. (Pubmed Central) - Jul 17, 2024
No differences in cardiac index, or any other evaluated hemodynamic parameters, length of hospital stay, nor mortality rate were noted between both groups. . The use of ivabradine in patients with AMI-CS was associated with a significant reduction in heart rate at 12 and 48 h, without affecting other hemodynamic parameters.
- || ivabradine / Generic mfg.
Review, Journal: Research progress in the application of ivabradine in children with cardiovascular diseases (Pubmed Central) - Jul 17, 2024
This article reviews the current research progress on the use of ivabradine in treating pediatric cardiovascular diseases both domestically and internationally, aiming to provide guidance for pediatric cardiologists. Citation:Chinese Journal of Contemporary Pediatrics, 2024, 26(7): 782-788.
- | atenolol / Generic mfg., ivabradine / Generic mfg., clozapine / Generic mfg.
New trial: Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial. (clinicaltrials.gov) - Jul 17, 2024
P=N/A, N=40, Recruiting, Sponsor: All India Institute of Medical Sciences, Bhubaneswar
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Neupogen (filgrastim) / Kyowa Kirin, Amgen
New trial: Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases (clinicaltrials.gov) - Jul 16, 2024
P=N/A, N=30, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- ||| Vectibix (panitumumab) / Amgen
Trial completion, Trial completion date, Trial primary completion date: Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Jul 16, 2024
P2, N=75, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Citation:Chinese Journal of Contemporary Pediatrics, 2024, 26(7): 782-788. Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Jul 2024 | Trial primary completion date: Mar 2025 --> Jul 2024
- |||||||||| Prolia (denosumab) / Amgen
New P3 trial: Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia (clinicaltrials.gov) - Jul 16, 2024
P3, N=440, Not yet recruiting, Sponsor: Xentria, Inc.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Late Breaking Abstract - Clinical efficacy of Tezepelumab in pre-selected non-Type 2 asthma patients (PS-10; Poster board no. 20) - Jul 16, 2024 - Abstract #ERS2024ERS_5846;
Conclusion This is the first case series demonstrating that patients with non-T2 asthma benefit from treatment with Tezepelumab regarding lung function, ACQ, and AQLQ. However, an extensive placebo-controlled trial is needed to confirm the clinically beneficial effects of Tezepelumab in non-T2 asthma patients.
- | Ibrance (palbociclib) / Pfizer
Journal: Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. (Pubmed Central) - Jul 16, 2024
However, an extensive placebo-controlled trial is needed to confirm the clinically beneficial effects of Tezepelumab in non-T2 asthma patients. Palbociclib met prespecified criteria to declare a signal of antitumor activity in patients with sarcoma and CDK4 amplification.
- || Vectibix (panitumumab) / Amgen
P2 data, Journal, Surgery: Interim Phase II Results Using Panitumumab-IRDye800CW During Transoral Robotic Surgery in Patients with Oropharyngeal Cancer. (Pubmed Central) - Jul 16, 2024
Palbociclib met prespecified criteria to declare a signal of antitumor activity in patients with sarcoma and CDK4 amplification. Results from this OPSCC patient cohort support further clinical assessment of FGS during TORS to aid resection of solid tumors.
- | Emcyt (estramustine) / Pfizer, Nippon Shinyaku, tapotoclax (AMG 176) / Amgen, TAK?632 / Takeda
Journal, IO biomarker: Prognostic signature based on S100 calcium-binding protein family members for lung adenocarcinoma and its clinical significance. (Pubmed Central) - Jul 16, 2024
Finally, small molecular compounds targeting prognostic genes were screened using CellMiner database, and molecular docking confirmed the binding of AMG-176, Estramustine, and TAK-632 with prognostic genes. In conclusion, we generated a prognostic signature with robust and reliable predictive ability, which may provide guidance for prognosis and treatment of LUAD.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis. (Pubmed Central) - Jul 16, 2024
In conclusion, we generated a prognostic signature with robust and reliable predictive ability, which may provide guidance for prognosis and treatment of LUAD. Treatment with romosozumab yields larger increases in bone mineral density than teriparatide after 12 months and a higher rate of completion.
- ||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, Adverse events: Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database. (Pubmed Central) - Jul 16, 2024
Infection-related AEs were highly associated with three CDK4/6 inhibitors, especially palbociclib and ribociclib, based on the real-world data from the FAERS database. However, further causality assessment is required.
- | cisplatin / Generic mfg.
Journal: Pharmacological inhibition of CDK4/6 impairs diffuse pleural mesothelioma 3D spheroid growth and reduces viability of cisplatin-resistant cells. (Pubmed Central) - Jul 16, 2024
Abemaciclib also synergized with cisplatin and reduced the viability of DPM cells with acquired resistance to cisplatin. Overall, our results suggest that CDK4/6 inhibitors alone or in combination with standard of care should be further explored for DPM therapy.
- | Epogen (epoetin alfa) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: Pharmacological Countermeasures for High Altitude (clinicaltrials.gov) - Jul 16, 2024
P4, N=18, Active, not recruiting, Sponsor: United States Army Research Institute of Environmental Medicine
Overall, our results suggest that CDK4/6 inhibitors alone or in combination with standard of care should be further explored for DPM therapy. Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Sep 2024 | Trial primary completion date: Aug 2022 --> Sep 2023
- || Imdelltra (tarlatamab-dlle) / Amgen
New P2 trial: DeLLphi-307: Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (clinicaltrials.gov) - Jul 16, 2024
P2, N=30, Not yet recruiting, Sponsor: Amgen
- ||| tapotoclax (AMG 176) / Amgen
Trial completion: AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 16, 2024
P1, N=142, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Sep 2024 | Trial primary completion date: Aug 2022 --> Sep 2023 Active, not recruiting --> Completed
- Bavencio (avelumab) / EMD Serono, Stivarga (regorafenib) / Bayer
Regomune study : A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC) (Pamplona Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1760;
- AMG 193 / Amgen
Phase 1 dose escalation and initial dose expansion results of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors (Barcelona Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1735;
- Stivarga (regorafenib) / Bayer
EREMISS Trial: a double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of Regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts). (Santander Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1713;
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib (Santander Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1711;
P2
Conclusions The LENVAGIST study met its primary endpoint. Lenvatinib leads to clinical benefits in pts presenting advanced GIST after failure of available TKIs.
- Vectibix (panitumumab) / Amgen, Lumakras (sotorasib) / Amgen
Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C (Madrid Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1578;
- Ibrance (palbociclib) / Pfizer, Zynyz (retifanlimab-dlwr) / Incyte
A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma (Alicante Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1457;
- | Rituxan (rituximab) / Roche
Enrollment closed: Split-Dose R-CHOP for Older Adults With DLBCL (clinicaltrials.gov) - Jul 15, 2024
P2, N=26, Active, not recruiting, Sponsor: University of Wisconsin, Madison
Lenvatinib leads to clinical benefits in pts presenting advanced GIST after failure of available TKIs. Recruiting --> Active, not recruiting
- || Imdelltra (tarlatamab-dlle) / Amgen
Enrollment closed: DeLLphi-300: Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Jul 15, 2024
P1, N=392, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
New trial: The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation (clinicaltrials.gov) - Jul 15, 2024
P=N/A, N=20, Not yet recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
- | Neulasta (pegfilgrastim) / Roche
New trial: Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma (EUDRACT) - Jul 15, 2024
P=N/A, N=87, Recruiting, Sponsor: The Affiliated People's Hospital of Ningbo University; The Affiliated People's Hospital of Ningbo University
- | Prolia (denosumab) / Amgen
New trial: Efficacy and safety of denosumab in promoting osseointegration of the prosthesis after total hip arthroplasty in elderly postmenopausal women with osteoporosis: a prospective real-world study (EUDRACT) - Jul 15, 2024
P=N/A, N=240, Recruiting, Sponsor: The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University
- | Prolia (denosumab) / Amgen
New trial: A Real-World Study of Migu Capsules Combined with Denosumab in Treatment of Dysmobility Syndrome (EUDRACT) - Jul 15, 2024
P=N/A, N=358, Not yet recruiting, Sponsor: Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Shuguang Hospital Affiliated to Shanghai University of Traditiona
- | Prolia (denosumab) / Amgen
New trial: A prospective randomized controlled study of Denosumab and zoledronic acid in the treatment of female osteoporotic fractures (EUDRACT) - Jul 15, 2024
P=N/A, N=300, Not yet recruiting, Sponsor: Shanghai Jiaotong University School of Medicine Affiliated Ruijin Hospital; Shanghai Jiaotong University School of Medicine Affiliated Ruijin Hospital
- | Repatha (evolocumab) / Amgen, Astellas
New trial: Preconditioning of PCSK9 inhibitors in the treatment of high-risk NSTE-ACS (EUDRACT) - Jul 15, 2024
P=N/A, N=208, Not yet recruiting, Sponsor: Shanxi Bethune Hospita; Shanxi Bethune Hospital
- | Ibrance (palbociclib) / Pfizer
New trial: To investigate the clinical regimen of Palbociclib combined with AZA/VEN in elderly patients with AML who cannot tolerate intensive chemotherapy(VP-A) (EUDRACT) - Jul 15, 2024
P=N/A, N=30, Recruiting, Sponsor: The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China; The First Affiliated Hos
- | Prolia (denosumab) / Amgen
New P4 trial: A Phase 4, Single Arm, Open Label Study for the Efficacy and Safety of Prolia in Treatment of Male Subjects With Osteoporosis in Mainland China (EUDRACT) - Jul 15, 2024
P4, N=100, Not yet recruiting, Sponsor: The Sixth People
- | Keytruda (pembrolizumab) / Merck (MSD), Stivarga (regorafenib) / Bayer
New P4 trial, Metastases: Safety and Efficacy of Regorafenib Combined with Pembrolizumab in Second-line Treatment of Advanced Hepatocellular Carcinoma: A single-center, single-arm, prospective study (EUDRACT) - Jul 15, 2024
P4, N=60, Not yet recruiting, Sponsor: The Third Affiliated Hospital of Sun Yat-Sen University; The Third Affiliated Hospital of Sun Yat-Sen University
- | Nplate (romiplostim) / Amgen, Kyowa Kirin
New P4 trial: Clinical study on the efficacy and safety of Roprostimin N01 (Relisheng (EUDRACT) - Jul 15, 2024
P4, N=40, Not yet recruiting, Sponsor: Tianjin Medical University General Hospital; Tianjin Medical University General Hospital
- | Blincyto (blinatumomab) / Astellas, Amgen
New P4 trial: A study to evaluate the clinical efficacy of chemotherapy combined with bispecific antibodies in the treatment of pediatric B-cell acute leukemia with high risk of relapse (EUDRACT) - Jul 15, 2024
P4, N=36, Not yet recruiting, Sponsor: Beijing Children's Hospital, Capital Medical University; Beijing Children's Hospital, Capital Medical University
- | Blincyto (blinatumomab) / Astellas, Amgen
New P4 trial: China Children's Leukemia Group (CCLG)-ALL2018 supplementary study on pediatric precursor B-cell acute lymphoblastic leukemia-Blinatumomab therapy (EUDRACT) - Jul 15, 2024
P4, N=102, Not yet recruiting, Sponsor: Beijing Children's Hospital, Capital Medical University; Beijing Children's Hospital, Capital Medical University
- | Prolia (denosumab) / Amgen
New P4 trial: A multicenter, prospective, observational real-world study evaluating the efficacy and safety of Denosumab Injection in the treatment of postmenopausal osteoporotic fractures (EUDRACT) - Jul 15, 2024
P4, N=1000, Not yet recruiting, Sponsor: The First Affiliated Hospital of Suzhou University; The First Affiliated Hospital of Suzhou University
- | Repatha (evolocumab) / Amgen, Astellas
New P4 trial: A prospective interventional open-label clinical study of PCSK9 inhibitors in the treatment of acute symptomatic intracranial arterial stenosis (EUDRACT) - Jul 15, 2024
P4, N=80, Recruiting, Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- | Enbrel (etanercept) / Pfizer, Amgen, Rituxan (rituximab) / Roche
New P4 trial: A multi-center randomized controlled clinical study of multi-target synergistic treatment for chronic active antibody-mediated rejection (EUDRACT) - Jul 15, 2024
P4, N=90, Not yet recruiting, Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
- | Prolia (denosumab) / Amgen
New P4 trial: Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone (EUDRACT) - Jul 15, 2024
P4, N=30, Not yet recruiting, Sponsor: Shanghai sixth people's hospital; Shanghai sixth people's hospital
- | Stivarga (regorafenib) / Bayer
New P2 trial: prospective phase II clinical study of TACE combined with candenizumab and regorafenib in the treatment of PD (L) -1 combined regimen resistant non-surgical hepatocellular carcinoma (EUDRACT) - Jul 15, 2024
P2, N=30, Not yet recruiting, Sponsor: Fujian Cancer Hospital; Fujian Cancer Hospital
- | Tyvyt (sintilimab) / Eli Lilly, Stivarga (regorafenib) / Bayer
New P2 trial: Efficacy and Safety of Recombinant Human Adenovirus Type 5 Injection Combined with HAIC, Sintilimab and Regorafenib in Patients with Advanced Liver Cancer Who Failed First-line Therapy: A Prospective Single-arm Study (EUDRACT) - Jul 15, 2024
P2, N=24, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
- | Kaitanni (cadonilimab) / Akesobio, Stivarga (regorafenib) / Bayer
New P2 trial: Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM (EUDRACT) - Jul 15, 2024
P2, N=44, Not yet recruiting, Sponsor: Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
- | Tyvyt (sintilimab) / Eli Lilly
New P2 trial: Phase II clinical study of rigorafenib and sintilimab in combination acupuncture for MSS type advanced colorectal cancer patients who have failed standard chemotherapy (EUDRACT) - Jul 15, 2024
P2, N=40, Recruiting, Sponsor: The First People
- | Stivarga (regorafenib) / Bayer, Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P2 trial: Lurbinectedin and doxorubicin plus regorafenib and PD-1 inhibitor as first-line treatment of locally advanced nonresectable or metastatic Soft Tissue Sarcoma: a prospective phase ? trial (EUDRACT) - Jul 15, 2024
P2, N=38, Not yet recruiting, Sponsor: Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences